Sale planned for ActivBiotics' products
Joseph Finn, the Assignee for the Benefit of Creditors of US firm ActivBiotics, as a result of growing interest from prospective buyers, has announced a development strategy for further advancement of the company's proprietary benzoxazinorifamycins as leading antibacterial drug candidates in combination antibiotic therapy. Rifalazil is the most developed of these compounds, though most of the interest for combination antibiotics has centered on New Chemical Entities.
The sale of ActivBiotics' assets, including rifalazil and the NCEs, is being conducted through an Assignment for the Benefit of Creditors. The bidding for these, which may be purchased separately or in combination, is scheduled for March 14.
For additional information on the terms of sale and to obtain a bidder's package, please contact Joseph Finn, CPA (jffinnjr@earthlink.net, phone +1 781 237 8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613, USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze